drugset / Trial / NCT04355962

Sevoflurane in COVID-19 ARDS (SevCov)

NCT04355962 ↗

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this trial is to study the effect of initial temporary sevoflurane sedation on mortality and persistent organ dysfunction (POD) in survivors at day 28 after ICU admission in the population of patients suffering from COVID-19 ARDS.

Timeline

Start
2020-04-23
Primary completion
2021-06-25
Completion
2021-07-16

Outcome

Missed primary endpoint

paper no difference in the primary endpoint with 11 (39%) sevoflurane and 13 (41%) control patients (p = 0.916) PMID 38536545 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Sevoflurane Other / unclassified — —
Comparator Dexmedetomidine Other / unclassified — —
Comparator Fentanyl Other / unclassified — —
Comparator Midazolam Small molecule — —
Comparator Propofol Small molecule — —